{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-021479","form_type":"8-K","ticker":"BDSX","cik":"0001439725","company_name":"BIODESIX INC","filed_at":"2022-11-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:50.669726+00:00","generated_at":"2026-06-22T08:41:14.964962+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Biodesix Q3 core lung diagnostic revenue up 102% to $9.2M; guidance at high end","bullets":["Core lung diagnostic revenue $9.2M (+102% YoY); total revenue $11.1M (+70% YoY).","Gross margin 67% vs 58% YoY, driven by growth in higher-margin core lung diagnostics.","Net loss $13.7M (up 19% YoY); cash $15.2M; raised $1.8M via equity; repaid $2.0M term loan.","All five core lung tests now covered by Medicare; added to Federal Supply Schedule for VA and Military Health.","2022 total revenue guidance expected at high end of $37.5M-$39.5M; minimal COVID/BioPharma in Q4."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-021479","json":"https://secwatch.observer/filing/0000950170-22-021479.json","markdown":"https://secwatch.observer/filing/0000950170-22-021479.md","text":"https://secwatch.observer/filing/0000950170-22-021479.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1439725/000095017022021479/0000950170-22-021479-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1439725/000095017022021479/bdsx-20221103.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T08:41:14.964962+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"83f3df55f33b3c48e1d5d3b08076a4473c242c01","claim":"BIODESIX INC reported third quarter ended September 30, 2022 results: revenue $11.1 million, net income $(0.34) per diluted share, EPS $(0.34) per diluted share. Guidance reaffirmed.","evidence_excerpt":"College of Chest Physicians (CHEST) annual meeting where we had several key presentations.” Third Quarter 2022 Financial Results For the three-month period ended September 30, 2022, as compared to the same period of 2021 (where applicable): • Total revenue of $11.1 million, an increase of 70%, driven primarily by strong year-over-year growth in core lung diagnostics: o Core lung diagnostic revenue of $9.2 million, reflected a year-over-year increase of 102% driven primarily by the increased adoption of Nodify Lung nodule management tests (Nodify CDT & Nodify XL2 tests) and the recent GeneStrat NGS commercial launch; o COVID-19 testing revenue of $1.3 million reflected a year-over-year increase of 154% that was driven primarily by testing volume under a now expired contract with the State of Colorado; o BioPharma Services revenue of $0.7 million decreased 55% year-over-year.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1439725/000095017022021479/0000950170-22-021479-index.htm","confidence":1.0,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third quarter ended September 30, 2022"},{"label":"Revenue","value":"$11.1 million"},{"label":"Net income","value":"$(0.34) per diluted share"},{"label":"EPS","value":"$(0.34) per diluted share"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}